Positive Phase 3 results from Moderna and Merck’s INTerpath-001 trial, announced August 19, 2026, represent the primary catalyst for trader sentiment on an FDA approval timeline for their personalized mRNA skin cancer vaccine (intismeran autogene) paired with Keytruda. The individualized neoantigen therapy met recurrence-free survival and distant metastasis-free survival endpoints in resected high-risk melanoma, marking the first late-stage success for an mRNA cancer vaccine and building on sustained five-year Phase 2 data showing roughly 49% risk reduction. Companies are now engaging regulators on filings, with potential submission in coming months and possible availability in 2027 under breakthrough therapy status. Recent FDA actions on competing melanoma therapies, such as Replimune’s oncolytic virus approval in August, highlight the competitive landscape while underscoring unmet need that could accelerate review. Full data presentation and any manufacturing or safety updates remain key near-term swing factors.